1. EachPod

74. New MS Therapies: ATA-188 and BTK inhibitors

Author
Dr. Gretchen Hawley PT, DPT, MSCS
Published
Wed 13 Jul 2022
Episode Link
https://www.doctorgretchenhawley.com/podcasts/the-msing-link/episodes/2147759101

Dr. Brandon Beaber is a board-certified neurologist with subspecialty training in multiple sclerosis and other immunological diseases of the nervous system and spasticity.   He is also the author of "resilience in the face of multiple sclerosis" (free to anyone who wants it;  just ask him on twitter)! 


Medical school: Drexel University college of medicine.


Residency:  Los Angeles Medical Center.


Fellowship: University of Southern California.  


 


In todays episode, we talk about two new ground breaking therapies for people with progressive MS:  ATA-188 & BTK inhibitors. They’re both still in clinical trial, but they’re looking promising with ATA-188 actually showing improvement in those with progressive MS! Let’s dive in!


 


Twitter: https://twitter.com/messages/media/1523785137397280775


Youtube: https://www.youtube.com/c/DrBrandonBeaber


 


Find a clinical trial near you: clinicaltrials.gov





Additional Resources: https://www.doctorgretchenhawley.com/insider


Reach out to Me[email protected] 


Website: www.MSingLink.com


Social


★ Facebook: https://www.facebook.com/groups/mswellness


★ Instagram: https://www.instagram.com/doctor.gretchen


★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1


 


→ Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse


→ Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram


→ The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

Share to: